These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 35577506)

  • 1. Targeting SNORA38B attenuates tumorigenesis and sensitizes immune checkpoint blockade in non-small cell lung cancer by remodeling the tumor microenvironment via regulation of GAB2/AKT/mTOR signaling pathway.
    Zhuo Y; Li S; Hu W; Zhang Y; Shi Y; Zhang F; Zhang J; Wang J; Liao M; Chen J; Qian H; Li D; Sun C
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35577506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 3. OTUB2 stabilizes U2AF2 to promote the Warburg effect and tumorigenesis via the AKT/mTOR signaling pathway in non-small cell lung cancer.
    Li J; Cheng D; Zhu M; Yu H; Pan Z; Liu L; Geng Q; Pan H; Yan M; Yao M
    Theranostics; 2019; 9(1):179-195. PubMed ID: 30662561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SIRT6 through PI3K/Akt/mTOR signaling pathway to enhance radiosensitivity of non-Small cell lung cancer and inhibit tumor progression.
    Xiong L; Tan B; Lei X; Zhang B; Li W; Liu D; Xia T
    IUBMB Life; 2021 Sep; 73(9):1092-1102. PubMed ID: 34033225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Grb2-associated binder 2 silencing impairs growth and migration of H1975 cells via modulation of PI3K-Akt signaling.
    Wang WJ; Mou K; Wu XF; Zhang JZ; Ren G; Qi JD; Xu YF; Yao X
    Int J Clin Exp Pathol; 2015; 8(9):10575-84. PubMed ID: 26617767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTPRH promotes the progression of non-small cell lung cancer via glycolysis mediated by the PI3K/AKT/mTOR signaling pathway.
    Wang S; Cheng Z; Cui Y; Xu S; Luan Q; Jing S; Du B; Li X; Li Y
    J Transl Med; 2023 Nov; 21(1):819. PubMed ID: 37974250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer.
    Yin C; Lin X; Wang Y; Liu X; Xiao Y; Liu J; Snijders AM; Wei G; Mao JH; Zhang P
    Cell Oncol (Dordr); 2020 Jun; 43(3):395-407. PubMed ID: 32006253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXC1-mediated LINC00301 facilitates tumor progression and triggers an immune-suppressing microenvironment in non-small cell lung cancer by regulating the HIF1α pathway.
    Sun CC; Zhu W; Li SJ; Hu W; Zhang J; Zhuo Y; Zhang H; Wang J; Zhang Y; Huang SX; He QQ; Li DJ
    Genome Med; 2020 Sep; 12(1):77. PubMed ID: 32878637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR mutations induce the suppression of CD8
    Huang H; Zhu X; Yu Y; Li Z; Yang Y; Xia L; Lu S
    J Transl Med; 2024 Jul; 22(1):653. PubMed ID: 39004699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR‑802 inhibits the aggressive behaviors of non‑small cell lung cancer cells by directly targeting FGFR1.
    Zhang J; Li J; Li S; Zhou C; Qin Y; Li X
    Int J Oncol; 2019 Jun; 54(6):2211-2221. PubMed ID: 30942425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FKBP4 Accelerates Malignant Progression of Non-Small-Cell Lung Cancer by Activating the Akt/mTOR Signaling Pathway.
    Meng W; Meng J; Jiang H; Feng X; Wei D; Ding Q
    Anal Cell Pathol (Amst); 2020; 2020():6021602. PubMed ID: 33354489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic SNORD12B activates the AKT-mTOR-4EBP1 signaling in esophageal squamous cell carcinoma via nucleus partitioning of PP-1α.
    Tian B; Liu J; Zhang N; Song Y; Xu Y; Xie M; Wang B; Hua H; Shen Y; Li Y; Yang M
    Oncogene; 2021 May; 40(21):3734-3747. PubMed ID: 33941854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UBQLN4 promotes the proliferation and invasion of non-small cell lung cancer cell by regulating PI3K/AKT pathway.
    He L; Chen H; Ruan B; He L; Luo M; Fu Y; Zou R
    J Cancer Res Clin Oncol; 2024 Jul; 150(7):335. PubMed ID: 38969831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
    Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
    PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
    Lu C; Shan Z; Hong J; Yang L
    Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergic effect of PD-1 blockade and endostar on the PI3K/AKT/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model.
    Wu J; Zhao X; Sun Q; Jiang Y; Zhang W; Luo J; Li Y
    Biomed Pharmacother; 2020 May; 125():109746. PubMed ID: 32106386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of long non-coding RNA RP11-708H21.4 is associated with poor prognosis for colorectal cancer and promotes tumorigenesis through regulating AKT/mTOR pathway.
    Sun L; Jiang C; Xu C; Xue H; Zhou H; Gu L; Liu Y; Xu Q
    Oncotarget; 2017 Apr; 8(17):27929-27942. PubMed ID: 28427191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells.
    Kumagai S; Togashi Y; Sakai C; Kawazoe A; Kawazu M; Ueno T; Sato E; Kuwata T; Kinoshita T; Yamamoto M; Nomura S; Tsukamoto T; Mano H; Shitara K; Nishikawa H
    Immunity; 2020 Jul; 53(1):187-203.e8. PubMed ID: 32640259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer.
    Wang J; Zhang R; Lin Z; Zhang S; Chen Y; Tang J; Hong J; Zhou X; Zong Y; Xu Y; Meng R; Xu S; Liu L; Zhang T; Yang K; Dong X; Wu G
    J Hematol Oncol; 2020 Jul; 13(1):99. PubMed ID: 32690037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CircHERC1 promotes non-small cell lung cancer cell progression by sequestering FOXO1 in the cytoplasm and regulating the miR-142-3p-HMGB1 axis.
    Cui Y; Wu X; Jin J; Man W; Li J; Li X; Li Y; Yao H; Zhong R; Chen S; Wu J; Zhu T; Lin Y; Xu J; Wang Y
    Mol Cancer; 2023 Nov; 22(1):179. PubMed ID: 37932766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.